Takeda expands in Brazil with Multilab buy
This article was originally published in Scrip
Takeda has agreed to pay up to Real540 million ($270 million) for the Brazilian company Multilab Indústria e Comércio de Produtos Farmacêuticos, expanding its reach in an important emerging market and also into the branded generics segment in the country.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.